EVALUATION OF TELOMERE LENGTH AND TELOMERASE ACTIVITY AS PROGNOSTIC MARKERS IN A PEDIATRIC PATIENT COHORT WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Author(s): ,
Monika Haubitz
Affiliations:
Hematology Adults, Laboratory for Hematopoiesis and Molecular Genetics, Department for BioMedical Research (DBMR),University of Bern,Bern,Switzerland
,
Axel Karow
Affiliations:
Division of Pediatric Hematology/Oncology, Department of Pediatrics,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
,
Ingrid Helsen
Affiliations:
Hematology Adults, Laboratory for Hematopoiesis and Molecular Genetics, Department for BioMedical Research (DBMR),University of Bern,Bern,Switzerland
,
Daniela Steiner
Affiliations:
Hematology Adults, Laboratory for Hematopoiesis and Molecular Genetics, Department for BioMedical Research (DBMR),University of Bern,Bern,Switzerland
,
Roland A. Ammann
Affiliations:
Division of Pediatric Hematology/Oncology, Department of Pediatrics,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
,
Mutlu Kartal-Kaess
Affiliations:
Division of Pediatric Hematology/Oncology, Department of Pediatrics,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
,
Jochen K. Rössler
Affiliations:
Division of Pediatric Hematology/Oncology, Department of Pediatrics,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
,
Elisabeth Oppliger Leibundgut
Affiliations:
Hematology Adults, Laboratory for Hematopoiesis and Molecular Genetics, Department for BioMedical Research (DBMR),University of Bern,Bern,Switzerland;Department of Hematology and Central Hematology Laboratory,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
Gabriela M. Baerlocher
Affiliations:
Department for BioMedical Research,University of Bern,Bern,Switzerland;Department of Hematology and Central Hematology Laboratory,Inselspital, Bern University Hospital, University of Bern,Bern,Switzerland
EHA Library. Haubitz M. Jun 14, 2019; 265984; PF194
Dr. Monika Haubitz
Dr. Monika Haubitz
Contributions
×
Abstract

Abstract: PF194

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background

Telomere length maintenance is tightly regulated with cell proliferation and senescence. To overcome physiologic telomere attrition with cell division, long-term repopulating cells like stem and progenitor cells upregulate telomerase. Pathophysiologically, over 90% of cancer cells reactivate telomerase enabling replicative immortality. Acute lymphoblastic leukemia (ALL) is the most common type of acute leukemias in pediatric patients (pts) and a neoplastic disease with a rapid clonal expansion.

Aims

We aimed to assess the mitotic history of the malignant ALL clone by telomere length (TL) and the potential of telomerase activity (TA) as a prognostic marker.

Methods
Peripheral blood samples collected before treatment initiation from 9 pediatric pts (4 females/ 5 males) with newly diagnosed pre-B cell ALL according to WHO 2016 criteria were analyzed for TL and TA. All pts were treated according to the international collaborative protocol (AIEOP-BFM ALL 2009 Registry) for children and adolescents with ALL. Based on (cyto)genetics and treatment response, 6 pts are in the intermediate and 3 pts are in the high-risk prognostic group. TL was measured in subsets of leukocytes by automated multicolor flow-FISH and compared to TL percentiles of the reference range obtained from over 400 healthy individuals. TA in leukocytes was analyzed by Telomere Repeat Amplification Protocol.

Results

The median age of the patient (pt) cohort was 10.8 years (range: 2.8-17.8) at diagnosis and study entry. The median leukocyte count was 9.8 G/L (1.4-38.6) with a median lymphocyte count of 2.0 G/L (0.6-8.1) and a median lymphoblast count of 6.37 G/L (0.2-31.27). The median TL value in blasts was with 5.2 kb (1.9-8.3) significantly (p=0.016) lower than 7.5 kb (6.9-9.3) for the B-cell subset. In 6/9 pt samples the TL values for blasts were below the 1st percentile of the TL reference range for lymphocytes whereas 3 pts had values between the 1st and 50th percentile. The median age-adjusted difference in TL (dTL=difference of TL to the 50th percentile for respective age) was -4.5 kb (-7.1-1.1) in blasts which was significantly higher than median dTL values in lymphocytes (-2.1 kb; range -6.2-0) and B-cells (-1.9 kb, range -2.6-0.4). Median TA in the mononuclear cell fraction containing blasts was 2.4 telomere-elongated products (TP)/cell (0.3-11.1), whereas no TA was detected in leukocytes from healthy donors. Notably, pediatric ALL pts with a high risk score (n=3) had a higher median TA of 5.5 TP/cell (2.2-11.1) than those with an intermediate risk score (n=6) with 1.8 TP/cell (0.3-3.3).

Conclusion
The significantly lower TL values in ALL blast cells from newly diagnosed pediatric pts reflect the mitotic history of the malignant clone with a high number of cell divisions. Despite measurable TA in ALL blasts, attrition of TL seemed not compensated and therefore, the extent of clonal proliferation might even be underestimated. Importantly, the higher median TA in blast cells of pts in the high-risk prognostic group indicates that TA could be an attractive prognostic marker. Further data on TL and TA on serial pt samples will identify if TA could also serve as predictive marker and therapeutic target.

Session topic: 2. Acute lymphoblastic leukemia - Clinical

Keyword(s): ALL, Clonal expansion, Prognostic factor

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies